denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.
Description:
While the number of therapies now available for Multiple Myeloma (MM) has grown tremendously, our understanding of the disease is still evolving. We now know that there are intricacies in even the most classic of signaling pathways. This session will describe cutting edge findings as they relate to some of the known and lesser-known factors in myelomagenesis.
Dr. Marta Chesi will summarize our current knowledge on the role of MYC in myeloma pathogenesis, with a particular focus on MYC involvement in the transition from stable monoclonal gammopathy to progressive MM disease in mice and humans. She will also describe the complexity of genomic events leading to both cis and trans activation of MYC in myeloma, as well as therapeutic approaches to target MYC.
Dr. Eugenio Morelli will discuss the emerging roles of non-coding RNAs in multiple myeloma. He will provide an overview of the recent studies dissecting the clinically relevant noncoding transcriptome in MM and the use of these molecules as biomarkers and predictors of outcomes. Dr. Morelli will present ongoing investigations leveraging the use of innovative RNA-targeting CRISPR technologies to discover the tumor-promoting functions of non-coding RNAs. He will highlight important roles for these molecules in the pathobiology of MM, such as the regulation of c-MYC transcriptional activity. Finally, Dr. Morelli will also convey a provocative scenario whereby the use of optimized antisense oligonucleotides or RNA-targeting small molecules will unlock the therapeutic potential of non-coding RNAs, turning them into valuable targets to cure MM.
Dr.Tom Cupedo will discuss the cellular interactions driving a tumor-supportive bone marrow environment in patients with multiple myeloma. He will provide an overview of the inflammatory alterations in the bone marrow stromal cell niche for malignant plasma cells, and link changes to activation of immune cells and presence of inflammatory proteins. First-line treatment significantly impacts pro-tumor bone marrow inflammation but fails to fully normalize the plasma cell niche. The impact of these findings on myeloma pathobiology will be discussed.
Dr. Marta Chesi will summarize our current knowledge on the role of MYC in myeloma pathogenesis, with a particular focus on MYC involvement in the transition from stable monoclonal gammopathy to progressive MM disease in mice and humans. She will also describe the complexity of genomic events leading to both cis and trans activation of MYC in myeloma, as well as therapeutic approaches to target MYC.
Dr. Eugenio Morelli will discuss the emerging roles of non-coding RNAs in multiple myeloma. He will provide an overview of the recent studies dissecting the clinically relevant noncoding transcriptome in MM and the use of these molecules as biomarkers and predictors of outcomes. Dr. Morelli will present ongoing investigations leveraging the use of innovative RNA-targeting CRISPR technologies to discover the tumor-promoting functions of non-coding RNAs. He will highlight important roles for these molecules in the pathobiology of MM, such as the regulation of c-MYC transcriptional activity. Finally, Dr. Morelli will also convey a provocative scenario whereby the use of optimized antisense oligonucleotides or RNA-targeting small molecules will unlock the therapeutic potential of non-coding RNAs, turning them into valuable targets to cure MM.
Dr.Tom Cupedo will discuss the cellular interactions driving a tumor-supportive bone marrow environment in patients with multiple myeloma. He will provide an overview of the inflammatory alterations in the bone marrow stromal cell niche for malignant plasma cells, and link changes to activation of immune cells and presence of inflammatory proteins. First-line treatment significantly impacts pro-tumor bone marrow inflammation but fails to fully normalize the plasma cell niche. The impact of these findings on myeloma pathobiology will be discussed.